Patents Assigned to Bioprojet
  • Patent number: 12145916
    Abstract: The present disclosure relates generally to a new crystalline form (i.e., polymorph) of pitolisant hydrochloride (Form II), pharmaceutical compositions comprising Form II, dosage forms comprising Form II, and methods of treating a disease or disorder with Form II, or with a pharmaceutical composition or dosage form comprising Form II.
    Type: Grant
    Filed: March 29, 2024
    Date of Patent: November 19, 2024
    Assignee: Bioprojet PHARMA
    Inventors: Marc Capet, Morgan Pauchet
  • Patent number: 12134608
    Abstract: The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: November 5, 2024
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 12059416
    Abstract: Disclosed are combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.
    Type: Grant
    Filed: November 26, 2021
    Date of Patent: August 13, 2024
    Assignee: BIOPROJET
    Inventors: Xavier Ligneau, Laurent Landais, David Perrin, Jeanne Marie Lecomte, Jean Charles Schwartz
  • Patent number: 11306069
    Abstract: Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: April 19, 2022
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 11229632
    Abstract: The present invention relates to combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: January 25, 2022
    Assignee: BIOPROJET
    Inventors: Xavier Ligneau, Laurent Landais, David Perrin, Jeanne Marie Lecomte, Jean Charles Schwartz
  • Patent number: 11179329
    Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 23, 2021
    Assignee: BIOPROJET PHARMA
    Inventors: Jeanne-Marie Lecomte, Jean-Charles Schwartz, Olivier Labeeuw, Marc Capet
  • Patent number: 11078183
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 3, 2021
    Assignee: BIOPROJET
    Inventors: Marc Capet, Jeanne-Marie Lecomte, Jean-Charles Schwartz
  • Patent number: 10952987
    Abstract: The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. A method is also provided for treating a subject in need thereof by administering the combination of adrenaline with an antidepressant. The pharmaceutical composition is to be administered by injection.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOPROJET
    Inventors: Jean-Charles Schwartz, Xavier Ligneau, Laurent François Gérard Landais, David Perrin, Jeanne-Marie Lecomte
  • Publication number: 20200093738
    Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.
    Type: Application
    Filed: March 21, 2018
    Publication date: March 26, 2020
    Applicant: BIOPROJET Pharma
    Inventors: Jeanne-Marie LECOMTE, Jean-Charles SCHWARTZ, Oliver LABEEUW, Marc CAPET
  • Publication number: 20200024256
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3 -methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 23, 2020
    Applicant: BIOPROJET Pharma
    Inventors: Marc CAPET, Jeanne-Marie LECOMTE, Jean-Charles SCHWARTZ
  • Patent number: 9439853
    Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: September 13, 2016
    Assignee: BIOPROJET
    Inventors: Jean-Stëphane Julien, Marc Maury, Jeanne-Marie Lecomte, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 9266867
    Abstract: The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: February 23, 2016
    Assignees: BIOPROJET, SUN PHARMA ADVANCED RESEARCH COMPANY LTD
    Inventors: Marc Capet, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Rajamannar Thennati, Ranjan Kumar Pal, Biswajit Samanta, Muthukumaran Natarajan Pillai, Japan Nitinkumar Desai, Dijixa Chandubhai Rana, Kaushik Dhanjubhai Prajapati, Sandeep Pankajbhai Pathak, Bhavesh M. Panchal, Jayraj D. Aradhye
  • Patent number: 9255101
    Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: February 9, 2016
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 9242959
    Abstract: The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: January 26, 2016
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 9029357
    Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 12, 2015
    Assignee: Bioprojet
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Denis Danvy, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 8809539
    Abstract: The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 19, 2014
    Assignees: Bioprojet, Sun Pharma Advanced Research Company Ltd
    Inventors: Marc Capet, Nicolas Levoin, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Jayraj Dilipbhai Aradhye, Muthukumaran Natarajan Pillai, Bhavesh Mohanbhai Panchal, Jignesh Kantilal Jivani, Biswajit Samanta, Ranjan Kumar Pal, Rajamannar Thennati
  • Patent number: 8802678
    Abstract: The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: August 12, 2014
    Assignee: Bioprojet
    Inventors: Marc Capet, Denis Danvy, Nicolas Levoin, Isabelle Berrebi-Bertrand, Thierry Calmels, Philippe Robert, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Xavier Ligneau
  • Publication number: 20140099316
    Abstract: The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.
    Type: Application
    Filed: April 10, 2012
    Publication date: April 10, 2014
    Applicants: SUN PHARMA ADVANCED RESEARCH COMPANY LTD., BIOPROJET
    Inventors: Marc Capet, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Rajamannar Thennati, Ranjan Kumar Pal, Biswajit Samanta, Muthukumaran Natarajan Pillai, Japan Nitinkumar Desai, Dijixa Chandubhai Rana, Kaushik Dhanjubhai Prajapati, Sandeep Pankajbhai Pathak, Bhavesh M. Panchal, Jayraj D. Aradhye
  • Publication number: 20130331423
    Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhoea.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 12, 2013
    Applicant: BIOPROJET
    Inventors: Jean-Stéphane Julien, Marc Maury, Jeanne-Marie Lecomte, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Publication number: 20130324507
    Abstract: The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 5, 2013
    Applicant: BIOPROJET
    Inventors: Isabelle BERREBI-BERTRAND, Xavier BILLOT, Thierry CALMELS, Marc CAPET, Stéphane KRIEF, Olivier LABEEUW, Jeanne-Marie LECOMTE, Nicolas LEVOIN, Xavier LIGNEAU